Document Detail


Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
MedLine Citation:
PMID:  16949099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Involvement of the prefrontal cortex in schizophrenia has been implicated by neuropsychological, as well as neuropathological and imaging studies. Reductions of N-acetylaspartate (NAA), an in vivo marker of neuronal integrity, have repeatedly been detected in the frontal lobes of patients with schizophrenia by proton magnetic resonance spectroscopy (1H-MRS). In chronic medicated patients, a positive correlation between NAA levels of the prefrontal cortex and cognitive functioning has been observed, but to date, there have been no studies in first-episode neuroleptic-naive patients. In this study, single-voxel 1H-MRS was used to investigate neuronal function of the dorsolateral prefrontal cortex in 15 first-episode and 20 chronic schizophrenic patients. Outcomes were compared to 20 age-matched healthy controls to assess the relationship between prefrontal metabolism and neuropsychological performance. Patients with chronic schizophrenia had significant reductions of NAA, glutamate/glutamine, and choline levels compared to first-episode patients and healthy controls. Furthermore, creatine and phosphocreatine were significantly reduced in both patient groups compared to healthy controls. In the neuropsychological tests, chronic schizophrenic patients performed significantly poorer in the Auditory Verbal Learning Task (AVLT) compared to first-episode patients. In both patient groups, NAA levels of the left frontal lobe significantly correlated with performances in verbal learning and memory. These results corroborate data from recent structural and spectroscopic imaging studies of the frontal lobes in schizophrenia, in which cortical gray matter reductions after onset of symptoms as well as reduced levels of NAA in chronic, but not in first-episode schizophrenic patients have been reported.
Authors:
Patricia Ohrmann; Ansgar Siegmund; Thomas Suslow; Anya Pedersen; Katharina Spitzberg; Anette Kersting; Matthias Rothermundt; Volker Arolt; Walter Heindel; Bettina Pfleiderer
Related Documents :
9300519 - The anthropometric assessment of dysmorphic features in schizophrenia as an index of it...
22595159 - Diagnostic performance of cmr imaging compared with emb in patients with suspected myoc...
15469189 - Spatial and temporal parameters of gait disturbances in schizophrenic patients.
11288369 - Family transactions and relapse in bipolar disorder.
20214929 - Event-related potential patterns and gender effects underlying facial affect processing...
21752649 - Simultaneous multiple hypertensive intracranial hemorrhages.
10487829 - Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry...
14039 - Diphenylpyraline (lergobine) in the treatment of patients suffering from allergic and v...
24533939 - Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.
Publication Detail:
Type:  Journal Article     Date:  2006-09-01
Journal Detail:
Title:  Journal of psychiatric research     Volume:  41     ISSN:  0022-3956     ISO Abbreviation:  J Psychiatr Res     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-04-03     Completed Date:  2007-07-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376331     Medline TA:  J Psychiatr Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  625-34     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, University of Muenster, Albert-Schweitzer Strasse 11, D-48149 Muenster, NRW, Germany. ohrmann@uni-muenster.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antipsychotic Agents / adverse effects,  therapeutic use*
Aspartic Acid / analogs & derivatives,  metabolism
Choline / metabolism
Chronic Disease
Cognition Disorders / drug therapy,  physiopathology*
Creatine / metabolism
Dominance, Cerebral / physiology
Energy Metabolism / drug effects,  physiology*
Female
Frontal Lobe / drug effects,  physiopathology*
Glutamic Acid / metabolism
Glutamine / metabolism
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy*
Male
Mental Recall / drug effects,  physiology
Middle Aged
Neurons / physiology
Phosphocreatine / metabolism
Prefrontal Cortex / drug effects,  physiopathology*
Psychiatric Status Rating Scales
Reference Values
Schizophrenia / drug therapy,  physiopathology*
Verbal Learning / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 56-84-8/Aspartic Acid; 56-85-9/Glutamine; 56-86-0/Glutamic Acid; 57-00-1/Creatine; 62-49-7/Choline; 67-07-2/Phosphocreatine; 997-55-7/N-acetylaspartate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  M129V variation in the prion protein gene and psychotic disorders: relationship to neuropsychologica...
Next Document:  Modeling and investigation of neural activity in the thalamus.